An Open-Label Pilot Study of Combined Augmentation With Creatine Monohydrate and 5-Hydroxytryptophan for Selective Serotonin Reuptake Inhibitor- or Serotonin-Norepinephrine Reuptake Inhibitor-Resistant Depression in Adult Women
Kious BM, Sabic H, Sung YH, Kondo DG, Renshaw P
Journal of clinical psychopharmacology · 21 citations
How it was studied
- Design
- Controlled clinical trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Government
- U.S. Department of Veterans Affairs
- Government
- BLRD VA
- Grants
- U.S. Department of Veterans Affairs (I01 BX002908)
Based on 2 listed funder(s).
Publication
- Published
- 2017-08-05 · J Clin Psychopharmacol · vol. 37 · issue 5 · pp. 578–583
- Publisher
- Lippincott Williams & Wilkins
- Cited
- 26 citations · more than 87% of similar papers · 2.3× the field average
- References
- 52 works
- Access
- Open access (repository copy)
- Research areas
- Treatment of Major Depression · Neurotransmitter Receptor Influence on Behavior · Digital Mental Health Interventions
- Keywords
- Major depressive disorder, Serotonin reuptake inhibitor, Reuptake inhibitor, Serotonin, Placebo, Medicine, Internal medicine, Hamilton Rating Scale for Depression, Depression (economics), Serotonin Uptake Inhibitors, Creatine, Psychology, Anesthesia, Fluoxetine
- MeSH
- humans, creatine, 5-hydroxytryptophan, antidepressive agents, treatment outcome, drug therapy, combination, pilot projects, drug resistance, adult, female, young adult
5 authors
From US
- Brent Michael Kious · correspondingVeterans Health Administration
- Hana SabicVeterans Health Administration
- Young-Hoon Sung · correspondingVeterans Health Administration
- Douglas G. Kondo · correspondingVeterans Health Administration
- Perry Franklin Renshaw · correspondingVeterans Health Administration
Abstract
Purpose
Many women with major depressive disorder (MDD) respond inadequately to standard treatments. Augmentation of conventional antidepressants with creatine monohydrate and 5-hydroxytryptophan (5-HTP) could correct deficits in serotonin production and brain bioenergetics associated with depression in women, yielding synergistic benefit. We describe an open-label study of 5-HTP and creatine augmentation in women with MDD who had failed selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) monotherapy.
Methods
Fifteen women who were adequately adherent to an SSRI or SNRI and currently experiencing MDD, with a 17-item Hamilton Depression Rating Scale (HAM-D) score of 16 or higher, were treated with 5 g of creatine monohydrate daily and 100 mg of 5-HTP twice daily for 8 weeks, with 4 weeks of posttreatment follow-up. The primary outcome was change in mean HAM-D scores.
Results
Mean HAM-D scores declined from 18.9 (SD, 2.5) at pretreatment visits to 7.5 (SD, 4.4) (P < 0.00001), a decrease of 60%. Participants did not experience any serious treatment-related adverse events.
Conclusions
Combination treatment with creatine and 5-HTP may represent an effective augmentation strategy for women with SSRI- or SNRI-resistant depression. Given the limitations of this small, open-label trial, future study in randomized, placebo-controlled trials is warranted.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.